CytoDyn, Inc. (CYDY)
0.20
0.00 (0.00%)
USD |
OTCM |
Oct 14, 16:00
CytoDyn Enterprise Value : 301.78M for Oct. 14, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 14, 2026 | 301.78M |
| October 13, 2026 | 300.15M |
| October 12, 2026 | 301.78M |
| October 09, 2026 | 301.78M |
| October 08, 2026 | 303.96M |
| October 07, 2026 | 301.64M |
| October 06, 2026 | 301.78M |
| October 05, 2026 | 301.78M |
| October 02, 2026 | 301.78M |
| October 01, 2026 | 300.33M |
| September 30, 2026 | 309.05M |
| September 29, 2026 | 304.69M |
| September 28, 2026 | 325.81M |
| September 25, 2026 | 341.05M |
| September 24, 2026 | 320.75M |
| September 23, 2026 | 313.42M |
| September 22, 2026 | 309.78M |
| September 21, 2026 | 327.31M |
| September 18, 2026 | 321.74M |
| September 17, 2026 | 316.33M |
| September 16, 2026 | 307.60M |
| September 15, 2026 | 302.80M |
| September 14, 2026 | 298.58M |
| September 11, 2026 | 298.22M |
| September 10, 2026 | 287.24M |
| Date | Value |
|---|---|
| September 09, 2026 | 301.49M |
| September 08, 2026 | 300.50M |
| September 04, 2026 | 300.76M |
| September 03, 2026 | 316.18M |
| September 02, 2026 | 314.87M |
| September 01, 2026 | 330.23M |
| August 31, 2026 | 355.16M |
| August 28, 2026 | 329.96M |
| August 27, 2026 | 328.86M |
| August 26, 2026 | 357.16M |
| August 25, 2026 | 340.95M |
| August 24, 2026 | 313.20M |
| August 21, 2026 | 303.86M |
| August 20, 2026 | 298.37M |
| August 19, 2026 | 290.13M |
| August 18, 2026 | 284.98M |
| August 17, 2026 | 286.83M |
| August 14, 2026 | 275.91M |
| August 13, 2026 | 285.92M |
| August 12, 2026 | 281.13M |
| August 11, 2026 | 272.96M |
| August 10, 2026 | 272.05M |
| August 07, 2026 | 271.58M |
| August 06, 2026 | 272.33M |
| August 05, 2026 | 272.27M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.431B |
| Alnylam Pharmaceuticals, Inc. | 29.70B |
| Anika Therapeutics, Inc. | 257.84M |
| Savara, Inc. | 835.07M |
| Vericel Corp. | 1.992B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.94M |
| Total Expenses (Quarterly) | 19.94M |
| EPS Diluted (Quarterly) | -0.0147 |
| Earnings Yield | -22.15% |
| Normalized Earnings Yield | -14.15 |